Investing in biotech and pharmaceuticals is always a bit of a wild card. The industry is often at the mercy of government regulators, and a clinical trial can always present unexpected challenges. When biotech and pharma stocks hit it big, however, its big news that often yields big returns. A lesser promoted biotech sector is the medical devices arena, which is hardly as sexy and....More>>>
Click to enlarge
Sarepta’s hearings. Or how to get a drug approved on emotional grounds. Source: Boston Globe.
In the world of biotech, amazing things sometimes happen. This article is about one such amazing thing: Sarepta’s (NASDAQ:SRPT) twin sister drug, company and stock.
The twin sister, of course, is AveXis (NASDAQ:AVXS). Consider the following:
Some analysts cite Hillary Clinton’s continued criticism of drug prices as a cause for a slump in biotech during the U.S. presidential campaign, but with the election behind us, many biotech enterprises saw at least a 9% increase due to Donald Trump’s victory.
Two companies in the biotech space entering the first quarter of 2017 may be in a position for their products, as well....More>>>
On Thursday, our Elite Opportunity Pronewsletter suggested getting into Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA: LABU) in part totake advantage of the January effect:
As a matter of fact, the entire biotech sector was the big performer yesterday, so we’re going to go ahead and take another shot with LABU, one of the primary bullish leveraged ETF’s tracking the....More>>>
Shares of Inovio Pharmaceuticals(INO) are climbing today after the biotech company announced that it would begin testing a Zika vaccine in Puerto Rico. Maxim’sJason McCarthy andJason Kolbert have the details:
CREDIT: Alex Wild Published Credit: Alex Wild Alex Wild
Inovio announced the initiation of a small clinical study (N=160) of its Zika vaccine, GLS-5700 (being developed....More>>>
ImmunoGen (NASDAQ:IMGN) is up 21.8% at 1:06 p.m. EST on no apparent news. Of course, it’s a biotech, so that’s often par for the course.
One possibility is that day traders are just doing their thing, following the momentum, which pushes the stock price higher. We’ll know in a few days if the share price returns to previous levels.
Welcome to another edition of “3 Things in Biotech You Should Learn Today,” a daily digest dedicated to helping you keep tabs on the fast-moving world of biotech and pharmaceutical research.
Let’s get started!
AstraZeneca whiplash continues with more durvalumab news
In a scrambling defense of disappointing MYSTIC results for its immune checkpoint inhibitor....More>>>
Welcome to another edition of “3 Things In Biotech You Should Learn Today,” a daily digest dedicated to helping you keep up with recent events in the biotech and pharmaceutical industries!
So what’s in store for today?
BioMarin makes itself a priority to the FDA in phenylketonuria
Phenylketonuria is a congenital disorder that can lead to severe complications....More>>>
ImmunoGen (NASDAQ:IMGN) is up 15.6% at 3:35 p.m. EDT on no news. The stock price bump might be a carryover from yesterday’s upgrade by Leerink Partners. Or maybe it’s short-sellers buying to cover their shorts after yesterday’s move. Or maybe it’s just because it’s a biotech and the sun came up today. Who knows?
We are coming into the fall and the third quarter, aftera surprisingly solid push fromthe markets over the summer. Analysts may say it isnt fundamentally sound but that does not detract from the gains. The high valuations, low volatility, no sell in May and go away and even weak economic data and earnings seem immaterial at this point.
The bull market is now over seven years old. Still, the....More>>>
Hormel Foods Corp (HRL) has been named to the Dividend Channel ”S.A.F.E. 25” list, signifying a stock with above-average ”DividendRank” statistics including a strong 2.0% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ”DividendRank” report.
According to the ETF Finder at ETF Channel, Hormel....More>>>
Donald Trump’s comments yesterday about the drug industry when he stated that drug companies were “getting away with murder” tanked biotech stocks and the general indexes. Investors in this space must be worried in the event that Trump gains some traction in this sector and records some wins. At present, he is like a dog with a bone. In the automotive sector, for example, he is....More>>>
Monday was a good start to the week for stocks, with major benchmarks climbing around half a percent on the day. Most market participants pointed to a lack of bad news over the weekend and anticipation about expected favorable economic data in the coming days as drivers of the generally positive attitude among investors.
But there are still plenty of factors that are preventing stocks overall....More>>>
Many established biotechs may outperform from here
Figure 1 shows dozens of stocks with double-digit price gain prospects in coming weeks and months. The better ones have experienced worst-case price drawdowns less than several of the DJ-30 stocks.
(used with permission)
Upside price rewards are from the behavioral (of what to do right, not wrong) analysis....More>>>
An estimated 36.7 million people around the world have HIV. Around 17 million of them are taking prescription drugs to treat their condition.The total global HIV drug market totals more than $20 billion annually.
There are several choices for investing in HIV drug stocks. Three of the best options for long-term investors are Gilead Sciences (NASDAQ:GILD), GlaxoSmithKline (NYSE:GSK), and Merck....More>>>